S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
GE   7.04 (-11.34%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
GE   7.04 (-11.34%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
GE   7.04 (-11.34%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
S&P 500   2,470.50 (-4.41%)
DOW   20,943.51 (-4.44%)
QQQ   182.31 (-4.25%)
AAPL   240.91 (-5.26%)
FB   159.60 (-4.32%)
MSFT   152.11 (-3.55%)
GOOGL   1,102.10 (-5.15%)
AMZN   1,907.70 (-2.16%)
CGC   13.58 (-5.83%)
NVDA   243.07 (-7.79%)
BABA   187.56 (-3.56%)
GE   7.04 (-11.34%)
AMD   43.66 (-4.00%)
T   28.05 (-3.77%)
ACB   0.81 (-11.00%)
F   4.40 (-8.90%)
NFLX   364.08 (-3.04%)
BAC   19.77 (-6.88%)
Log in

NASDAQ:VERU - Veru Stock Price, Forecast & News

$3.10
-0.17 (-5.20 %)
(As of 04/1/2020 04:00 PM ET)
Today's Range
$3.04
Now: $3.10
$3.19
50-Day Range
$2.58
MA: $3.69
$4.58
52-Week Range
$1.18
Now: $3.10
$4.74
Volume215,007 shs
Average Volume387,751 shs
Market Capitalization$202.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.34
Veru Inc. operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation. The company's urology drug candidates include Tamsulosin delayed release sachet and Tamsulosin XR capsules that are under bioequivalence study for the treatment of benign prostatic hyperplasia; and Solifenacin delayed release granules, which is under bioequivalence study for the treatment of overactive bladder. Its urology drug candidates also comprise Tadalafil and Finasteride combination capsules that are under bioequivalence study for the treatment of men with lower urinary tract symptoms and enlarged prostate. The company's oncology drug candidate includes VERU-944, which is in Phase II clinical trial for the treatment of hot flashes in men on prostate cancer hormonal therapies; and VERU-111, an oral alpha and beta tubulin inhibitor, which is under Phase 1b/2 study for the treatment of metastatic prostate, breast, endometrial, ovarian, and pancreatic cancers. It serves agencies, health care distributors, non-government organizations, ministries of health, and other governmental agencies through distributors and retailers primarily in the United States, Brazil, Spain, France, and the United Kingdom. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was founded in 1896 and is headquartered in Miami, Florida.
Read More
Veru logo

Industry, Sector and Symbol

Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryPersonal Products
SectorMedical
Current SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.80 million
Book Value$0.50 per share

Profitability

Net Income$-12,020,000.00

Miscellaneous

Employees171
Market Cap$202.10 million
Next Earnings Date5/20/2020 (Estimated)
OptionableOptionable

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.


Veru (NASDAQ:VERU) Frequently Asked Questions

How has Veru's stock been impacted by COVID-19 (Coronavirus)?

Veru's stock was trading at $3.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VERU shares have decreased by 3.1% and is now trading at $3.10. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Veru?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Veru.

When is Veru's next earnings date?

Veru is scheduled to release its next quarterly earnings announcement on Wednesday, May 20th 2020. View our earnings forecast for Veru.

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) posted its quarterly earnings results on Wednesday, February, 12th. The company reported ($0.05) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.02) by $0.03. The company had revenue of $10.58 million for the quarter, compared to analyst estimates of $9.30 million. Veru had a negative net margin of 36.58% and a negative return on equity of 40.45%. View Veru's earnings history.

What price target have analysts set for VERU?

3 brokerages have issued 1 year target prices for Veru's stock. Their forecasts range from $6.00 to $12.00. On average, they expect Veru's stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price. View analysts' price targets for Veru.

Has Veru been receiving favorable news coverage?

Headlines about VERU stock have been trending very negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Veru earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutVeru.

Are investors shorting Veru?

Veru saw a decrease in short interest in the month of March. As of March 13th, there was short interest totaling 365,000 shares, a decrease of 5.2% from the February 27th total of 385,100 shares. Based on an average trading volume of 363,300 shares, the short-interest ratio is presently 1.0 days. Currently, 0.8% of the shares of the stock are short sold. View Veru's Current Options Chain.

Who are some of Veru's key competitors?

What other stocks do shareholders of Veru own?

Who are Veru's key executives?

Veru's management team includes the following people:
  • Dr. Mitchell S. Steiner M.D., F.A.C.S, Chairman, Pres & CEO (Age 58)
  • Dr. Harry Fisch, Vice Chairman & Chief Corp. Officer (Age 60)
  • Mr. O. B. Parrish, Co-Founder & Director (Age 86)
  • Ms. Michele Greco, CFO, Exec. VP of Fin. & Chief Admin. Officer (Age 60)
  • Dr. K. Gary Barnette Ph.D., Chief Scientific Officer (Age 51)

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How do I buy shares of Veru?

Shares of VERU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $3.10.

How big of a company is Veru?

Veru has a market capitalization of $202.10 million and generates $31.80 million in revenue each year. The company earns $-12,020,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis. Veru employs 171 workers across the globe. View additional information about Veru.

What is Veru's official website?

The official website for Veru is http://www.veruhealthcare.com/.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (NASDAQ VERU)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  393
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe VERU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VERU will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel